SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

Part of paid clinical trials in San Antonio, Texas.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT02592421
Phase
PHASE3
Status
Completed

Conditions

  • Type II Diabetes Mellitus

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    SGLT2 inhibitor (dapagliflozin)
  • Placebo — DRUG
    Placebo Comparator

Study Details

In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.

Key Dates

Start date
Oct 23, 2015
Status verified
Sep 2020
Primary completion
Oct 1, 2018
Completion
Oct 31, 2019

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Dapagliflozin
    20 subjects will receive dapagliflozin 10mg
  • Placebo Comparator: Placebo
    10 subjects will receive placebo

Primary Outcome Measure

Change in Plasma Glucose Concentration [ Time Frame: Baseline to 240-300 minutes ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Health Science Center at San AntonioSan AntonioTexas78229-

Find similar trials in San Antonio, TX

By research site
University of Texas Health Science Center at San Antonio· San Antonio, TX

Related Studies